Literature DB >> 21706482

Cystogenic potential of CD133+ progenitor cells of human polycystic kidneys.

Raquel Carvalhosa1, Ilaria Deambrosis, Paola Carrera, Chiara Pasquino, Francesca Rigo, Maurizio Ferrari, Fedele Lasaponara, Andrea Ranghino, Luigi Biancone, Giuseppe Segoloni, Benedetta Bussolati, Giovanni Camussi.   

Abstract

In autosomal dominant polycystic kidney disease, cysts arise focally and disrupt normal renal tissue leading to renal failure. In the present study, we show that cyst-lining cells express the stem cell marker CD133. CD133+ progenitor cells isolated from polycystic kidney, carrying mutations of PKD genes, showed a dedifferentiated phenotype similar to CD133+ progenitor cells from normal kidney. However, these cells were more proliferative and presented a defective epithelial differentiation phenotype with respect to normal renal CD133+ cells as they were not able to express all tubular epithelial cell markers when cultured in epithelial differentiation medium. Polycystic CD133+ cells, in contrast to normal renal CD133+ cells, formed cysts in vitro in a three-dimensional culture system and in vivo when injected subcutaneously within Matrigel in SCID mice. Rapamycin treatment reduced in vitro proliferation of polycystic CD133+ cells and decreased cystogenesis both in vitro and in vivo. The in vitro epithelial differentiation was only partially improved by rapamycin. These results indicate that polycystic CD133+ cells retain a dedifferentiated phenotype and the ability to generate cysts.
Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21706482     DOI: 10.1002/path.2920

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  3 in total

Review 1.  Therapeutic use of human renal progenitor cells for kidney regeneration.

Authors:  Benedetta Bussolati; Giovanni Camussi
Journal:  Nat Rev Nephrol       Date:  2015-08-04       Impact factor: 28.314

2.  Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study.

Authors:  William E Braun; Jesse D Schold; Brian R Stephany; Rita A Spirko; Brian R Herts
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

3.  Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients.

Authors:  Atieh Makhlough; Soroosh Shekarchian; Reza Moghadasali; Behzad Einollahi; Seyedeh Esmat Hosseini; Neda Jaroughi; Tina Bolurieh; Hossein Baharvand; Nasser Aghdami
Journal:  Stem Cell Res Ther       Date:  2017-05-23       Impact factor: 6.832

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.